Trials / Completed
CompletedNCT04857606
Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 609 in Subjects With Non-alcoholic Fatty Liver Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to assess the safety and tolerability of AMG 609 when administered subcutaneously as single doses in participants with non-alcoholic fatty liver disease (NAFLD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 609 | Single dose of AMG 609 administered as a subcutaneous injection. |
| DRUG | Placebo | Single dose of placebo administered as a subcutaneous injection. |
Timeline
- Start date
- 2021-05-24
- Primary completion
- 2023-07-19
- Completion
- 2023-07-19
- First posted
- 2021-04-23
- Last updated
- 2023-11-07
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04857606. Inclusion in this directory is not an endorsement.